stockrow
Friday 6 November 2026
Export ENOV’s income statement to Excel — free account
Enovis Corporation
ENOV Healthcare Medical Devices
Enovis Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 6.66% from fiscal 2024.
- Revenue
- +1.79%
- EPS
- +100.6%
- Free cash flow
- +20.3%
- Total debt
- −7.45%
Quarter to September 2026, against a year earlier
27.07
1.55
−5.42%
Follow ENOV
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.68 | 0.57 | 0.52 | 0.46 | |
P/FCF ratio |
76.33 | 36.30 | 18.73 | 15.36 | |
P/Operating CF |
17.17 | 54.44 | 15.89 | 14.95 | |
P/B ratio |
1.02 | 0.88 | 0.81 | 0.71 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.24 | 1.14 | 1.07 | 1.00 | |
EV/EBITDA |
12.65 | 9.44 | 7.98 | 7.49 | |
EV/Operating CF |
12.80 | 10.69 | 9.12 | 8.93 | |
EV/FCF |
139.62 | 72.29 | 38.71 | 33.26 | |
Quick Ratio |
0.80 | 0.78 | 0.74 | 0.76 | |
Current Ratio |
2.02 | 2.04 | 1.98 | 2.15 | |
Net Debt/EBITDA |
16.55 | 16.18 | 14.38 | 0.00 | |
Debt/Assets |
33.82% | 34.60% | 34.11% | 33.68% | |
Debt/Equity |
0.87 | 0.90 | 0.87 | 0.84 | |
Asset Turnover |
0.53 | 0.52 | 0.52 | 0.56 | |
Operating CF/Net income |
(0.17) | (2.73) | (63.05) | 22.78 | |
Capex/Depreciation |
(0.10) | (0.72) | (0.62) | 0.00 | |
Interest Coverage |
(66.84) | 0.71 | 2.17 | 0.44 | |
Research and Development Expense of Revenue |
5.45% | 5.35% | 5.44% | 5.60% | |
Selling, General and Administrative Expense of Revenue |
46.97% | 48.00% | 45.25% | 46.42% | |
Intangible Assets out of Total Assets |
0.51 | 0.50 | 0.49 | 0.48 | |
Share Based Compensation of Revenue |
1.41% | 1.49% | 1.54% | 1.39% | |
Graham Net Nets |
(0.75) | (0.85) | (0.90) | (0.93) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(77.74%) | (87.38%) | (93.04%) | (50.41%) | |
Free Cash Flow Yield |
1.31% | 2.76% | 5.34% | 6.51% | |
Revenue per Share |
10.09 | 10.28 | 10.12 | 9.55 | |
Operating CF per Share |
1.55 | 0.42 | 1.30 | 1.22 | |
Capex per Share |
(0.99) | (0.92) | (0.76) | (0.62) | |
Free Cash Flow per Share |
0.57 | (0.50) | 0.54 | 0.60 | |
Cash per Share |
0.64 | 0.58 | 0.22 | 0.22 | |
Shareholders Equity per Share |
26.14 | 25.81 | 25.68 | 25.57 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
26.14 | 25.81 | 25.68 | 25.57 | |
Free Cash Flow |
32.29 | (28.85) | 31.14 | 34.99 | |
Working Capital |
608.59 | 631.02 | 602.64 | 667.74 | |
Capital Expenditures |
(56.25) | (52.80) | (43.89) | (36.50) | |
Net Current Asset Value |
(1,135.78) | (1,113.08) | (1,072.27) | (992.38) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.10 | 0.09 | 0.08 | 0.07 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
424.91 | 439.91 | 447.77 | 430.03 | |
Average Payables |
183.31 | 200.89 | 203.24 | 199.61 | |
Average Inventory |
565.75 | 594.23 | 614.94 | 616.95 | |
Average Assets |
4,276.76 | 4,353.65 | 4,393.76 | 4,084.46 | |
Average Common Equity |
2,028.12 | 2,049.86 | 2,030.06 | 1,759.63 |
Columns are period end dates · fundamentals updated 5 Nov 2026